Edition:
United Kingdom

People: Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

8.45USD
8:21pm BST
Change (% chg)

$-0.12 (-1.40%)
Prev Close
$8.57
Open
$8.57
Day's High
$8.57
Day's Low
$8.11
Volume
152,097
Avg. Vol
439,337
52-wk High
$15.47
52-wk Low
$6.00

Wiggans, Thomas 

Mr. Thomas G. Wiggans serves as Chairman of the Board, Chief Executive Officer, Co-Founder of the Company. Mr. Wiggans founded our company in August 2010, has served as our Chief Executive Officer and a member of our board of directors since August 2010 and has served as the Chairman of our board of directors since April 2014. He currently serves on the board of directors of Annexon Biosciences, Inc., a privately-held biotechnology company. Mr. Wiggans has also served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx from March 2005 until its acquisition by Amgen in October 2013, Sangamo Biosciences from June 2008 until June 2012, Somaxon Pharmaceuticals, Inc. from June 2008 until May 2012 and as Chairman of the board of directors of Excaliard Pharmaceuticals, Inc. from October 2010 until its acquisition by Pfizer in December 2011. From October 2007, Mr. Wiggans served as Chairman of the board of directors of Peplin and in August 2008, he became its Chief Executive Officer, serving in these positions until Peplin’s acquisition by LEO Pharma in November 2009. Previously, Mr. Wiggans served as Chief Executive Officer of Connetics from 1994, and as Chairman of the board of directors of Connetics from January 2006, and he served in these positions until December 2006 when Connetics was acquired by Stiefel Laboratories. From 1992 to 1994, Mr. Wiggans served as President and Chief Operating Officer of CytoTherapeutics Inc., a biotechnology company. From 1980 to 1992, Mr. Wiggans served at Ares-Serono S.A. in various management positions including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Mr. Wiggans began his career with Eli Lilly. In addition, Mr. Wiggans is a member of the board of directors of the Biotechnology Innovation Organization and is a member of the board of trustees of the University of Kansas Endowment Association.

Basic Compensation

Total Annual Compensation, USD 3,664,930
Restricted Stock Award, USD 706,250
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 4,371,180

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 10,000 104,940.00
Name Fiscal Year Total

Thomas Wiggans

4,371,180

Luis Pena

2,519,500

Andrew Guggenhime

2,360,030

Christopher Horan

2,358,110

Christopher Griffith

833,154

Lori Lyons-Williams

2,704,630
As Of  31 Dec 2018